Engineered Mesenchymal Stromal Cells for Solid Tumours: Integrating Bibliometric Landscape Analysis with Preclinical Meta-Analysis of Efficacy
Cancer Treatment and Research Communications · 2026-11 · 101534
DOI: 10.1016/j.ctarc.2026.101534 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Treatment and Research Communications, 2026-11. Verfasst von Jie Zhang und 3 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Mesenchymal stromal/stem cells (MSCs) are widely investigated as tumour‑homing carriers for anticancer agents, but the robustness of preclinical efficacy evidence amidst rapidly expanding literature remains uncertain.
Methods
We performed a dual synthesis: a bibliometric analysis (Web of Science, 2008–2025) mapping publication trends, collaboration, co‑citation, and keyword bursts using CiteSpace; and a meta‑analysis of controlled animal studies of engineered viable MSCs in solid tumours, estimating tumour burden (Hedges’ *g*) and overall survival (hazard ratio, HR) via random‑effects models with Hartung–Knapp adjustments, sensitivity analyses, and SYRCLE risk‑of‑bias assessment.
Results
The bibliometric search yielded 13,933 records; annual output rose from 220 (2008) to a peak of 1,245 (2021) and remained >900 through 2025. Legacy networks showed the USA as the most central contributor (centrality 0.39), with clusters on EMT, extracellular vesicles, and targeted therapy. The meta‑analysis included 32 reports. Engineered MSCs significantly reduced tumour burden versus MSC controls (*g* = −2.38, 95% CI −3.23 to −1.53; I² = 83.3%) and improved survival (HR = 0.17, 95% CI 0.08–0.34; I² = 71.6%). Sensitivity analyses confirmed benefit, but prediction intervals crossed the null, funnel‑plot asymmetry (Egger *p* < 0.05) and mostly unclear SYRCLE domains suggested small‑study effects and reporting deficiencies.
Conclusions
The field shows large average efficacy but high heterogeneity and methodological limitations. Our findings support payload‑specific, pre‑registered, and standardised replication studies rather than a blanket class effect.
Zitieren
APA
Zhang, J., Yuan, C., Zhao, J., & Zhang, L. (2026). Engineered Mesenchymal Stromal Cells for Solid Tumours: Integrating Bibliometric Landscape Analysis with Preclinical Meta-Analysis of Efficacy. Cancer Treatment and Research Communications, 101534. https://doi.org/10.1016/j.ctarc.2026.101534
Vancouver
Zhang J, Yuan C, Zhao J, Zhang L. Engineered Mesenchymal Stromal Cells for Solid Tumours: Integrating Bibliometric Landscape Analysis with Preclinical Meta-Analysis of Efficacy. Cancer Treatment and Research Communications. 2026:101534. doi:10.1016/j.ctarc.2026.101534
BibTeX
@article{Zhang2026,
author = {Zhang, Jie and Yuan, Chunluan and Zhao, Jingjing and Zhang, Lei},
title = {Engineered Mesenchymal Stromal Cells for Solid Tumours: Integrating Bibliometric Landscape Analysis with Preclinical Meta-Analysis of Efficacy},
journal = {Cancer Treatment and Research Communications},
year = {2026},
pages = {101534},
doi = {10.1016/j.ctarc.2026.101534}
}
EUVIMED